SCHEMBL3604078

SCHEMBL3604078

Cc1nc(NC(=N)N)sc1-c1csc(Nc2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.61
MAPT P10636 9/20 0.60
MEN1 O00255 9/20 0.60
KMT2A Q03164 9/20 0.60
ALDH1A1 P00352 8/20 0.60
GAA P10253 6/20 0.60
HPGD P15428 4/20 0.60
LMNA P02545 2/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
HTT P42858 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C19 P33261 2/20 0.58
RAB9A P51151 2/20 0.58
CYP3A4 P08684 1/20 0.58
PKM P14618 1/20 0.58
MCL1 Q07820 1/20 0.58
POLB P06746 2/20 0.58
HSD17B10 Q99714 3/20 0.57
NPC1 O15118 3/20 0.57
USP2 O75604 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608656 0.89 MAPT (0.76) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL8226945 0.85 MEN1 (0.65) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL3595812 0.85 MEN1 (0.69) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL3614813 0.83 TRPV4 (0.68) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL3607067 0.80 MEN1 (0.73) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL4527541 0.79 MAPT (0.71) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL4524238 0.77 MEN1 (0.84) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL2380037 0.77 RAB9A (0.61) PLAUMAPTMEN1KMT2AALDH1A1
SCHEMBL4533727 0.76 GAA (0.98) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL6924901 0.76 PLAU (1.00) PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 PLAU 4084/4885MAPT 2/4885MEN1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.